{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:04:36Z","timestamp":1720382676719},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Internal Grant Agency of the Czech Ministry of Health","award":["AZV 16-31092A"],"award-info":[{"award-number":["AZV 16-31092A"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.leukres.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T22:43:50Z","timestamp":1535755430000},"page":"29-38","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group"],"prefix":"10.1016","volume":"73","author":[{"given":"David","family":"Belada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vit","family":"Prochazka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Janikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vit","family":"Campr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Blahovcova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pytlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Sykorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Pirnos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Duras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"February (2)","key":"10.1016\/j.leukres.2018.08.019_bib0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"October (28)","key":"10.1016\/j.leukres.2018.08.019_bib0010","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"December (12)","key":"10.1016\/j.leukres.2018.08.019_bib0015","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"January (9759)","key":"10.1016\/j.leukres.2018.08.019_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"486","key":"10.1016\/j.leukres.2018.08.019_bib0025","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"issue":"October (19)","key":"10.1016\/j.leukres.2018.08.019_bib0030","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"issue":"February (6)","key":"10.1016\/j.leukres.2018.08.019_bib0035","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"February (4)","key":"10.1016\/j.leukres.2018.08.019_bib0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"June (6)","key":"10.1016\/j.leukres.2018.08.019_bib0045","first-page":"867","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams","year":"2018","journal-title":"Br J Haematol. 2016"},{"issue":"May (5)","key":"10.1016\/j.leukres.2018.08.019_bib0050","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/10428194.2015.1079313","article-title":"Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database","volume":"57","author":"Janikova","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"4064","key":"10.1016\/j.leukres.2018.08.019_bib0055","article-title":"Rituximab maintenance for two years in previously untreated follicular lymphoma: no difference in outcome between patients receiving treatment at two month versus three month interval","volume":"130","author":"Roy","year":"2017","journal-title":"Blood"},{"issue":"484","key":"10.1016\/j.leukres.2018.08.019_bib0060","article-title":"Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial","volume":"130","author":"Kahl","year":"2017","journal-title":"Blood"},{"issue":"September (5)","key":"10.1016\/j.leukres.2018.08.019_bib0065","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"June","key":"10.1016\/j.leukres.2018.08.019_bib0070","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"April (2)","key":"10.1016\/j.leukres.2018.08.019_bib0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"January\u2013 February (1)","key":"10.1016\/j.leukres.2018.08.019_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.regg.2017.04.010","article-title":"Comprehensive geriatric assessment and intervention proposal in a patient with a diffuse large B-cell lymphoma","volume":"53","author":"Palicio Mart\u00ednez","year":"2018","journal-title":"Rev. Esp. Geriatr. Gerontol."},{"issue":"April (4)","key":"10.1016\/j.leukres.2018.08.019_bib0085","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"October (1)","key":"10.1016\/j.leukres.2018.08.019_bib0090","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol."},{"issue":"March (8)","key":"10.1016\/j.leukres.2018.08.019_bib0095","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"May","key":"10.1016\/j.leukres.2018.08.019_bib0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"September ; (27)","key":"10.1016\/j.leukres.2018.08.019_bib0105","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"Vitolo","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"March (7)","key":"10.1016\/j.leukres.2018.08.019_bib0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"August (23)","key":"10.1016\/j.leukres.2018.08.019_bib0115","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"December (23)","key":"10.1016\/j.leukres.2018.08.019_bib0120","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1158\/1078-0432.CCR-13-1511","article-title":"End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis","volume":"19","author":"Pyo","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"October (10)","key":"10.1016\/j.leukres.2018.08.019_bib0125","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","article-title":"Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study","volume":"93","author":"Witzens-Harig","year":"2014","journal-title":"Ann. Hematol."},{"issue":"Feb(5)","key":"10.1016\/j.leukres.2018.08.019_bib0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T19:04:20Z","timestamp":1538766260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"alternative-id":["S0145212618302029"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.019","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}